Can GLP-1 Medications Help People With Cancer? What a New Study Shows
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
A new breast cancer study found that women who used GLP-1 medications had about 60% lower all-cause mortality at both 5 and 10 years than women who did not, which has researchers genuinely excited while they wait for stronger proof (JAMA Network Open).
GLP-1 medications are the weight-loss and diabetes drugs many people know by brand names, and they work as GLP-1 receptor agonists, which is the medical term for medicines that activate a receptor in your body that helps with blood sugar and appetite. The findings are promising, and they are also early, so this guide walks through what the study actually showed and what it does not yet prove.
Who This Helps
This is for anyone taking or considering a GLP-1 medication who has seen headlines linking these drugs to cancer and wants the real story. It helps people with a personal or family history of cancer who are weighing their options with a doctor. It also helps caregivers and family members trying to make sense of fast-moving research without the hype.
Does This Change Your GLP-1 Treatment Right Now?
For most people, this research is a reason for measured optimism, not a reason to change anything on your own. The study looked at survival in women already diagnosed with breast cancer, so it does not mean a GLP-1 medication is a cancer treatment, and it does not mean you should start or stop one because of these results (JAMA Network Open). Any decision about these medicines belongs in a conversation with your own doctor, who knows your history. If you take an FDA-approved GLP-1 medication like Ozempic or Wegovy, the safest path is to keep following your prescriber's plan and bring any questions about this research to your next visit. If your worry is about side effects rather than survival, we sorted the real concerns from the rumors in our piece on whether GLP-1 medications cause hair loss, cancer, or fatigue.
What the New Breast Cancer Study Found
Researchers ran a retrospective cohort study, which means they looked back at health records that already existed rather than running a live experiment (JAMA Network Open). They drew from a very large dataset of 841,831 patients diagnosed with breast cancer between 2008 and 2023 and used a matching method to create fair comparison groups (JAMA Network Open).
The headline result is the survival difference. All-cause mortality was about 60% lower at both 5 and 10 years among the women who used a GLP-1 medication compared with those who did not, with an even larger gap when GLP-1 users were compared with women taking insulin or metformin (JAMA Network Open). The study also found a large relative improvement in recurrence-free survival, which means going longer without the cancer coming back, though the absolute difference there was small (JAMA Network Open). The commentary accompanying the study noted that no prior research has found a survival difference this large with GLP-1 medications in any cancer (JAMA Network Open).
Why Researchers Are Excited and Cautious at the Same Time
A physician commentary published with the study called the promise real and urged that the research move forward quickly (JAMA Network Open). The same commentary was careful to lay out what this kind of study cannot answer, and those limits matter for how you read the result.
To count as a GLP-1 user, a patient only had to fill two prescriptions, and the study did not capture how long people actually used the medicine, which specific drug they took, how much weight they lost, or how well their diabetes was controlled (JAMA Network Open). Because it is retrospective, it can show a strong association but cannot prove the medication caused the better survival (JAMA Network Open). One comparison adds a question mark: when GLP-1 users were measured against people taking an SGLT2 inhibitor, another diabetes drug, the survival difference was not statistically significant (JAMA Network Open). The study authors and the commentary both called for randomized clinical trials, which are the experiments that can actually test cause and effect (JAMA Network Open).
The Bigger Picture: Weight, Obesity, and Cancer
Part of why this research is plausible at all is the long-known link between excess weight and cancer. The National Cancer Institute reports that people with overweight or obesity face a higher risk of at least 13 types of cancer, including breast, colorectal, endometrial, and esophageal cancers (National Cancer Institute). Weight-loss surgery has been shown to lower the risk of several obesity-related cancers, which helped spark interest in whether medical weight loss might do something similar (JAMA Network Open).
GLP-1 medications have already shown signals in this area. A large 2024 study of more than 1.6 million patients with type 2 diabetes found that GLP-1 users had a lower risk of 10 of the 13 obesity-associated cancers compared with people taking insulin (JAMA Network Open). That same study did not find a significant drop in postmenopausal breast cancer or thyroid cancer risk, which points to an important distinction (JAMA Network Open). Lowering the chance of getting a cancer and improving survival after a diagnosis are two different questions, and the evidence is stronger for some cancers than others. We covered the prevention side in our look at what the evidence says about GLP-1s and cancer risk.
What About Safety, Thyroid, and Advanced Cancer
The research on survival does not erase the safety labels these medicines already carry. FDA-approved GLP-1 medicines include a boxed warning about a risk of thyroid C-cell tumors seen in rodents, and they are not for people with a personal or family history of medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 (Ozempic Prescribing Information). Whether these medicines cause that tumor in humans is still unknown, but the contraindication stands (Ozempic Prescribing Information).
The breast cancer study also left out the sickest patients. People with stage 4 cancer were not included, and the accompanying commentary noted that using a GLP-1 medication in advanced cancer is more likely to carry added risks, partly because reduced eating and weight loss can be harmful for someone who is already frail (JAMA Network Open). This is exactly the kind of situation where the choice depends on the person, which is why your oncologist and prescriber should make these calls with you rather than a headline.
What This Means for You
The honest summary is that GLP-1 medications look promising in cancer research, and the strongest new finding is about survival in women with breast cancer rather than preventing cancer in the first place. The size of the survival difference is striking, and it comes from a study design that can point the way without proving cause. If you are living with cancer, at higher risk, or simply curious, the useful move is to bring this research to your care team and ask how it fits your situation. Steady, informed conversations will serve you better than either fear or hype.
Final Takeaway
The promise here is real, and so is the need for more proof. A large study found markedly better survival among women with breast cancer who used GLP-1 medications, and a companion commentary urged researchers to keep going while being clear about what is still unknown. These are associations from past records, not results from the controlled trials that can confirm cause and effect. For now, the medicines remain what they have been: tools for weight and diabetes management that some doctors and patients choose together. If your story includes cancer or a higher risk of it, your care team is the right place to weigh what this means for you. The science is moving fast, and it is worth following with a calm and curious eye.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Do GLP-1 medications treat cancer? No. A new study found better survival among women with breast cancer who used GLP-1 medications, but these drugs are not approved as a cancer treatment and the study could not prove they caused the benefit. They remain medicines for weight management and type 2 diabetes, and any use during cancer care should be guided by your oncologist.
How strong is the evidence that GLP-1s help cancer survival? The breast cancer finding is striking, with about 60% lower all-cause mortality among GLP-1 users, but it comes from a retrospective study that looks back at existing records. That design can show a strong association and cannot confirm cause and effect, which is why the researchers called for randomized clinical trials.
Do GLP-1 medications lower the risk of getting cancer? Some research points that way. A large 2024 study found GLP-1 users with type 2 diabetes had a lower risk of 10 of 13 obesity-associated cancers compared with insulin users, though it did not find a significant reduction in postmenopausal breast or thyroid cancer. Lowering the risk of developing a cancer is a separate question from improving survival after a diagnosis.
Are GLP-1 medications safe if I have a history of cancer? For many people they are considered reasonable, but the answer depends on the type and stage of cancer and your general health. FDA-approved GLP-1 medicines carry a boxed warning about thyroid C-cell tumors and are not for people with a personal or family history of medullary thyroid cancer or MEN 2, so this is a decision to make with your doctor.
Should I start a GLP-1 medication to prevent cancer? No. There is no approval or recommendation to use GLP-1 medications for cancer prevention, and the current evidence comes from observational studies rather than trials designed to answer that question. If you are considering one of these medicines, talk with your provider about your own risks and goals.
Sources
Keep Reading
A plain-language look at what peer-reviewed studies actually show about hair loss, thyroid and pancreatic cancer, and fatigue on GLP-1 medications.
Peer-reviewed research shows GLP-1 medications do not meaningfully increase cancer risk. Here’s what large human studies say in 2026.
Worried about GLP-1 side effects like stomach paralysis or “Ozempic face”? This guide debunks myths with real research and clear answers.
Categories
Curated by
